No warranty against infringement of any patent, copyright or trademark is made or implied. (NYSE: ALR) announced today a definitive agreement for Abbott to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership. Abbott Laboratories assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. 1, 2016 / PRNewswire / - Abbott (NYSE: ABT) and Alere Inc. Alere i Influenza A & B is the first molecular diagnostic test that delivers actionable, lab-accurate results in less than 15 minutes on a user-friendly platform. It is not intended to supplement, modify or supersede any information provided with respect to the medical use of the product. (NYSE: ALR ), a global leader in rapid diagnostics, today announced that its Alere i RSV test has received 510. A/B and RSV assay, a molecular diagnostic rapid test and com- pared it to LDA and two established, non-molecular rapid assays. Nucleic acid amplification technologies (NAATs) have become fundamental tools in molecular diagnostics, due to their ability to detect small amounts of target molecules. This information is not a substitute for the advice of a healthcare professional, nor is it a recommendation for any particular course of treatment. More than 110,000 of us are helping millions of people to live better and healthier, every day around the world. However, Abbott Laboratories does not guarantee their accuracy or completeness or the recommendations contained herein, NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. With headquarters in north suburban Chicago, Abbott serves people in more than 160 countries with leading medical devices, diagnostics, nutrition products and branded generic medicines. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced it has received IVD CE marking in Europe for the Alere q HIV-1/2. The information and recommendations contained herein are based upon tests believed to be reliable. WALTHAM, Mass., Ma/PRNewswire/ - Alere Inc. K140377, K140647: VERIGENE ENTERIC PATHOGEN NUCLEIC ACID TEST (EP. Eight portable diagnostic molecular instruments (Alere q, GeneXpert Edge, GeneXpert Omni, Genedrive, PanNAT, Revogene, cobas Liat and ID Now) that are commercially available or in the launching stage are presented and evaluated in the context of the mobile microbiology concept, with particular emphasis on technical features and environmental. For information regarding lithium batteries in Abbott equipment, please email or call +1-57 Alere I Influenza A & B 2, Alere I Instrument, Alere I Influenza A & B Control Swab Kit.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |